SCHEMBL26214034

SCHEMBL26214034

CCCNS(=O)(=O)c1ccc(OC(C)CC)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55
ALDH1A1 P00352 13/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
PKM P14618 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.47
TP53 P04637 1/20 0.46
L3MBTL1 Q9Y468 2/20 0.45
USP2 O75604 1/20 0.45
TSHR P16473 1/20 0.44
LMNA P02545 3/20 0.43
POLB P06746 2/20 0.43
MEN1 O00255 1/20 0.43
HTT P42858 1/20 0.43
KMT2A Q03164 1/20 0.43
MAPT P10636 2/20 0.43
KDM4E B2RXH2 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5770948 0.79 ALDH1A1 (0.77) CA12CA1CA2CA9ALDH1A1
SCHEMBL20314698 0.79 ALDH1A1 (0.58) CA12CA1CA2CA9ALDH1A1
SCHEMBL8388722 0.78 CA12 (0.62) CA12CA1CA2CA9ALDH1A1
SCHEMBL7926322 0.76 CA12 (0.60) CA12CA1CA2CA9ALDH1A1
SCHEMBL13431944 0.76 PTGDR (0.43) CA1CA2CA9ALDH1A1PKM
SCHEMBL9229020 0.76 CA1 (0.69) CA12CA1CA2CA9ALDH1A1
SCHEMBL21556105 0.76 CA2 (0.58) CA12CA1CA2CA9ALDH1A1
SCHEMBL21556165 0.76 CA2 (0.58) CA12CA1CA2CA9ALDH1A1
SCHEMBL9923581 0.76 CA2 (0.58) CA12CA1CA2CA9ALDH1A1
SCHEMBL14411353 0.75 ALDH1A1 (0.46) ALDH1A1PKML3MBTL1TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER UNIVERSITE CLAUDE BERNARD LYON 1 (FR) 2023-09-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230278983-A1 INDOLE DERIVATIVES AND USES THEREOF FOR TREATING A CANCER CSNK2A1, IDO1, CSNK2A3 CA12 666/4885CA1 689/4885CA2 342/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.